Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck
Robert I. Haddad(Georgetown University), Deborah Jean Lee Wong(University of California, Los Angeles), Makoto Tahara(National Cancer Center Hospital East), Muneyuki Masuda(National Hospital Organization Kyushu Cancer Center), M. Ballinger, Ye Guo(Army Medical University), Jérôme Fayette(Université Claude Bernard Lyon 1), Nabil F. Saba(Emory University), Ricard Mesı́a(Institut d'Investigació Biomédica de Bellvitge), Andrzej Kawecki, Arunee Dechaphunkul(Prince of Songkla University), Vaikunth Cuchelkar, Maria Teixeira(Instituto Português de Oncologia de Coimbra Francisco Gentil), Monika Kaul, José Dinis(IPO Porto), Kevin J. Harrington(Royal Marsden NHS Foundation Trust), Agnes Lau, Cláudia Vaz de Melo Sette(Faculdade de Medicina do ABC), Kumar Prabhash(Homi Bhabha National Institute), Tao Jiang(Tongji University), Ching-Yun Hsieh(China Medical University), Christina Matheny, Yibing Yan(Anhui Medical University), Maria Grazia Ghi(Istituto Oncologico Veneto)
Cited by 42
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k